-- 周二上午晚些时候，美国存托凭证（ADR）上涨，欧洲股市在美国交易，标普欧洲精选ADR指数上涨0.3%，至1844.78点。 欧洲大陆方面，领涨的股票包括生物制药公司Grifols (GRFS)和互联网浏览器公司Opera (OPRA)，分别上涨3.1%和2.9%。紧随其后的是制药公司诺和诺德 (NVO)和半导体公司Sequans Communications (SQNS)，分别上涨2.3%和1.6%。 欧洲大陆方面，领跌的股票包括石油炼制公司Equinor (EQNR)和生物技术公司Evaxion (EVAX)，分别下跌2.5%和1.2%。紧随其后的是石油天然气公司Eni (E)和制药公司Ascendis Pharma (ASND)，分别下跌1%和0.5%。 英国股市涨幅居前的主要是生物制药公司Bicycle Therapeutics (BCYC)和Biodexa Pharmaceuticals (BDRX)，分别上涨6.2%和4.2%。紧随其后的是生物制药公司NuCana (NCNA)和邮轮运营商Carnival (CUK)，分别上涨3.4%和3%。 英国和爱尔兰股市跌幅居前的主要是生物技术公司Trinity Biotech (TRIB)和制药公司Silence Therapeutics (SLN)，分别下跌1.7%和1.5%。紧随其后的是烟草公司British American Tobacco (BTI)和石油天然气公司Shell (SHEL)，分别下跌1.4%和1.1%。
Related Articles
Research
Research Alert: CFRA Maintains Hold Rating On Shares Of United Rentals Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target price to $1,100 from $950 following a strong first quarter, valuing shares at 20.5x our 2027 EPS outlook of $54.28 (in line with previous estimate; 2026 EPS also in line). We believe a higher multiple is justified given URI's firming market leadership within an expanding rental equipment industry. A robust Q1 beat enabled URI to raise its full-year revenue guidance to $16.9B-$17.4B and adjusted EBITDA to $7.625B-$7.875B, citing momentum heading into a busy season. With leverage well below historical levels, we believe accretive M&A deals could serve as a potential catalyst for additional guidance increases. Margin compression has been a sticky issue for URI, but Q1 indicated that pricing may have turned around and that headwinds are starting to ease as quarterly results begin to lap when tariff-related inflation began to pick-up. We remain cautious on margins, though are encouraged by signs of stabilization. New project activity is likely supporting pricing trends, in our view.
$URI
Equities
Petro Rabigh Emerges From Loss in Q1; Revenue Grows
Rabigh Refining and Petrochemical (SASE:2380), d/b/a Petro Rabigh, said Sunday it swung back to profit in the first quarter of 2026, while revenue increased year over year.Net profit attributable to shareholders of the issuer for the three months ended March 31 was 1.47 billion Saudi riyals, compared with the attributable loss of 691 million riyals earlier. EPS moved to 0.88 riyal from a loss per share of 0.41 riyal.The Tadawul-listed oil refining and petrochemical company's revenue was 14.85 billion riyals, compared with 11.21 billion riyals a year ago.
$SASE:2380
Research
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.
$HIG